Moreover, MLL frequently hosts international research cooperation directly: For instance through exchange programs, our test procedures and data repositories, but also by allowing guest researchers to shadow the work of our facility and by sitting on national and international work groups.

We also support research institutions around the world to produce new insight in the field of leukemia diagnostics and emergence, as well as in the rollout of new procedures and applications for routine diagnostics in the facilities themselves.

Publications

Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.

Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters - an analysis of 3082 patients. Blood 2008;111(5):2527-2537.

Bacher U, Haferlach C. FISH in der Diagnostik hämatologischer Neoplasien. Medizinische Genetik 2008.

Bacher U, Zander AR, Haferlach T, Schnittger S, Fehse B, Kröger N. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008;42(3):145-157.

Berg T, Fliegauf M, Burger J, Staege MS, Liu S, Martinez N, Heidenreich O, Burdach S, Haferlach T, Werner MH, Lübbert M. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO. Haematologica 2008:93(11):1728-1733.

Fabarius A, Giehl M, Rebacz B, Krämer A, Frank O, Haferlach C, Duesberg P, Hehlmann R, Seifarth W, Hochhaus A. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica. 2008;93(8):1145-54.

Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B, Pucciarini A, Pileri S, Meloni G, Martelli MF, Haferlach T, Schnittger S. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008;93(5):775-779.

Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, Brown P, Pane F, Mancini M, Martelli MP, Pileri S, Haferlach T, Haferlach C, Schnittger S. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008;93(3):439-442.

Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini B. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008;105(10):3945-3950.

Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genet Cytogenet 2008;187(2):101-11.

Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia 2008;22(8):1539-1541.

1 / 3